At the recent American Society of Clinical Oncology (ASCO; Alexandria, Virginia) conference in Chicago, the world of precision medicine was led by the ability to single out particular 'markers' often genetic in nature that defined a particular individual, and appeared to predict his likely response to a drug or combination. This phase of oncology development is not new, but it is accelerating now, based on newer technologies enabling more affordable and rapid gene sequencing and manipulating technologies.